Prediction Models for Lung Cancer Screening
(PASI Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method for screening lung cancer using prediction models to catch the disease early when it's more treatable. The focus is on Veterans, particularly those who smoke or recently quit, as they have a higher risk of lung cancer. The trial compares different methods, including the Prediction Augmented Screening Initiative, which provides new tools for healthcare providers and patient management systems, against usual care to determine which is more effective in increasing screening rates. Veterans who have never been screened for lung cancer and meet specific smoking history criteria may be suitable for this trial. As an unphased trial, it offers Veterans the chance to contribute to innovative research that could enhance early detection of lung cancer.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this prediction model is safe for lung cancer screening?
Research has shown that the Prediction Augmented Screening Initiative enhances lung cancer screening. This initiative includes tools for primary care doctors, tested in other studies, which have increased screening rates. Importantly, no reports of harm or safety issues have emerged, indicating likely safety.
Tools for managing lung cancer screening, such as dashboards and outreach kits, have also been studied and found safe. These tools assist doctors and health teams in managing screenings more effectively.
When both primary care tools and management dashboards are used together, studies suggest they improve screening rates. Again, no safety concerns have been reported.
Overall, these tools aim to help doctors and health teams enhance lung cancer screening without posing any safety risk to patients.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to improve lung cancer screening using innovative tools. Unlike traditional screening methods, which often rely solely on standard imaging and physician assessments, this trial introduces prediction models and specialized tools to enhance early detection. The "PCP facing tools" provide primary care providers with advanced resources, while the "LCS team population management tools" offer a dashboard and outreach toolkit for proactive patient management. These features could lead to more personalized and timely screenings, potentially catching lung cancer earlier and improving patient outcomes.
What evidence suggests that this trial's treatments could be effective for improving lung cancer screening uptake?
Research has shown that prediction models can help detect lung cancer earlier. Studies have found that screening with low-dose CT scans can reduce the risk of dying from lung cancer by up to 25%. In this trial, participants may receive different interventions to enhance screening rates. One arm will use PCP-facing tools, another will use LCS team population management tools, a third will combine both interventions, and a fourth will follow usual care. Digital tools can help patients understand their options and make informed choices. Technology-based management tools can also increase screening rates among high-risk groups. Using these methods together might further improve screening rates and save more lives.16789
Who Is on the Research Team?
Nichole Tanner, MD
Principal Investigator
Ralph H. Johnson VA Medical Center, Charleston, SC
Are You a Good Fit for This Trial?
This trial is for individuals eligible for lung cancer screening, particularly focusing on Veterans who are at high risk but have low screening rates. It aims to improve early detection in this group, with an emphasis on reducing disparities and increasing uptake among Black Veterans.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Implementation of prediction-augmented lung cancer screening using primary care-facing informatics tools and LCS team population management tools
Follow-up
Participants are monitored for lung cancer detection rates, uptake among high-benefit Veterans, and complications from invasive procedures
What Are the Treatments Tested in This Trial?
Interventions
- Prediction Augmented Screening Initiative
Find a Clinic Near You
Who Is Running the Clinical Trial?
VA Office of Research and Development
Lead Sponsor